Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older

Jabagi, Marie Joelle; Botton, Jérémie; Bertrand, Marion; Weill, Alain; Farrington, Paddy; Zureik, Mahmoud and Dray-Spira, Rosemary (2022). Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older. JAMA, 327(1) pp. 80–82.

DOI: https://doi.org/10.1001/jama.2021.21699

Abstract

The BNT162b2 mRNA vaccine (Pfizer-BioNTech) was the first SARS-CoV-2 vaccine authorized and most widely used in older persons in France. Although no increases in cardiovascular events were reported in the phase 3 trials,1 questions emerged once the vaccine was used on a large scale because older people were underrepresented in the trials. We evaluated the short-term risk of severe cardiovascular events among French people aged 75 years or older after the administration of the BNT162b2 mRNA vaccine

Viewing alternatives

Metrics

Item Actions

Export

You can export this page using these formats Digital Object Identifier - DOI